(RTTNews) – Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor, from Japan’s Takeda Pharmaceutical Co. Ltd. (TAK).
The acquisition further expands Axsome’s industry-leading Central Nervous System (CNS) portfolio with a novel mechanism for neuropsychiatric conditions.
Axsome intends to develop the selective inhibitor for the treatment of schizophrenia and Tourette syndrome. It plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026.
Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia. The selective PDE10A inhibitor has demonstrated a favorable safety and tolerability profile in clinical studies in over 360 individuals to date.
Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect. Takeda received an upfront payment and is eligible to receive additional payments related to development, regulatory, and commercial milestones for the first two indications, as well as royalties related to potential global net sales.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
